Comment on CMS-2026-1256-0002
Medexus Pharma, Inc.SupportBusiness
Summary: Medexus Pharma, Inc., a specialty pharmaceutical company, supports the proposed continuation of New Technology Add-on Payments (NTAP) for GRAFAPEX and the existing framework for NTAP continuations. The company also urges CMS to maintain flexibility in evaluating "newness" and "substantial clinical improvement" (SCI) criteria to ensure that the NTAP program remains accessible for innovative treatments without imposing overly onerous evidentiary standards.
Good afternoon. Please see the attached letter for comments from Medexus Pharma, Inc. (Medexus) to the FY 2027 IPPS Proposed Rule. Thank you for the opportunity to submit our comments.